Clarivate Q3 2026 net loss more than doubles to $80.8 million
CLVT•Clarivate’s third-quarter 2026 net loss more than doubled to $80.8 million, including a $62.2 million noncash goodwill impairment charge. Revenue fell 9% to $567.9 million, and the Life Sciences & Healthcare segment sale generated $488.4 million in net cash proceeds.
1. Quarterly results
Clarivate’s third-quarter 2026 net loss more than doubled to $80.8 million, driven by a $62.2 million noncash Life Sciences & Healthcare goodwill impairment charge. Revenues, including discontinued operations, fell 9% year over year to $567.9 million, primarily due to inorganic disposals; the segment sale closed October 6, 2026, generating $488.4 million in net cash proceeds.
